Persistent splenomegaly due to littoral cell angiomatosis in venetoclax-induced undetectable minimal residual disease of chronic lymphocytic leukemia

Ann Hematol. 2023 Mar;102(3):681-682. doi: 10.1007/s00277-022-05067-4. Epub 2022 Dec 21.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Neoplasm, Residual
  • Rituximab / therapeutic use
  • Splenomegaly

Substances

  • venetoclax
  • Rituximab
  • Bridged Bicyclo Compounds, Heterocyclic